{"title":"Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.","authors":"Siqi Qiu, Zhipeng Zong, Kang He","doi":"10.1080/1750743X.2025.2529152","DOIUrl":null,"url":null,"abstract":"<p><p>The impact of immune checkpoint inhibitors (ICIs) on transplant rejection remains controversial. We report a case of a hepatocellular carcinoma patient who received Atezolizumab plus Bevacizumab regimen prior to liver transplantation and developed steroid-refractory T cell-mediated rejection combined with antibody-mediated rejection post-transplant. Given the short discontinuation and outstanding tumor response, we believe that the use of ICIs prior to transplantation contributed to this complex condition. The rejection was successfully cured with anti-thymocyte globulin (ATG) combined with an anti-CD20 monoclonal antibody (Rituximab). After 9-months follow-up, no tumor recurrence occurs. This case highlights the unique immune activation state affecting both T and B lymphocytes induced by ICIs. It also provides a case reference for the use of intensive immunosuppressive regimens in ICI recipients experiencing adverse reactions.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2529152","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The impact of immune checkpoint inhibitors (ICIs) on transplant rejection remains controversial. We report a case of a hepatocellular carcinoma patient who received Atezolizumab plus Bevacizumab regimen prior to liver transplantation and developed steroid-refractory T cell-mediated rejection combined with antibody-mediated rejection post-transplant. Given the short discontinuation and outstanding tumor response, we believe that the use of ICIs prior to transplantation contributed to this complex condition. The rejection was successfully cured with anti-thymocyte globulin (ATG) combined with an anti-CD20 monoclonal antibody (Rituximab). After 9-months follow-up, no tumor recurrence occurs. This case highlights the unique immune activation state affecting both T and B lymphocytes induced by ICIs. It also provides a case reference for the use of intensive immunosuppressive regimens in ICI recipients experiencing adverse reactions.
期刊介绍：
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
